Overall, this new knowledge may help tailor treatment regimens for patients with B-NHLs and subsets of CLL patients, such as those presenting with Richter’s transformation or those receiving ibrutinib, which may synergize with venetoclax by reducing expression of MCL1 and BCLXL [36,37]. The gene discussed is BCL2L1; the disease is B-cell chronic lymphocytic leukemia.